Groundbreaking CRISPR Screen Technology Rapidly Determines Disease Mechanism from Tissues

Thanks to over a decade of advancements in human genetics, scientists have compiled extensive lists of genetic variations linked to a wide array of human diseases. However, understanding how a gene contributes to disease is quite different from knowing how to treat the disease. Each risk gene can affect multiple cell types, and pinpointing how these cell types—and even individual cells—influence a gene and its role in disease progression is crucial for developing effective treatments. Now, a new CRISPR screen method allows for the rapid analysis of brain cell types associated with key developmental genes, providing insights into the genetic and cellular mechanisms underlying various neurological disorders at an unprecedented level.

Developed at Scripps Research (La Jolla, CA, USA), the new technique, called in vivo Perturb-seq, utilizes CRISPR-Cas9 technology combined with single-cell transcriptomic analysis as a readout to measure the effects of genomic alterations on individual cells. By employing CRISPR-Cas9, researchers can introduce specific changes into the genome during brain development and then analyze how these alterations impact individual cells, assessing thousands simultaneously. Previously, methods for inserting genetic perturbations into brain tissue were slow, often requiring days or weeks, which hampered the study of gene functions in neurodevelopment. However, this new screening method enables the rapid expression of perturbation agents in living cells within 48 hours, allowing researchers to quickly observe the roles of specific genes across different cell types within a very short time frame.

This method also offers unprecedented scalability—researchers were able to profile over 30,000 cells in a single experiment, a rate 10-20 times faster than traditional methods. In regions such as the cerebellum, they gathered tens of thousands of cells, reaching areas that previous labeling techniques could not. A pilot study using this innovative technology revealed that genetic perturbations produce varied effects across different cell types. This finding is significant as these affected cell types are often the targets for specific diseases or genetic variants. With this new technology, the team is poised to deepen their understanding of neuropsychiatric disorders and the relationship between specific cell types and brain regions. Going forward, they are keen on applying this technology to other cell types and organs to explore a broad spectrum of diseases in terms of tissue development and aging.

“We know that certain genetic variants in our genome can make us vulnerable or resilient towards different diseases, but which specific cell types are behind a disease? Which brain regions are susceptible to the genome mutations in those cells? These are the kinds of questions we're trying to answer,” said senior author Xin Jin, PhD, an assistant professor in the Department of Neuroscience at Scripps Research. “With this new technology, we want to build a more dynamic picture across brain region, across cell type, across the timing of disease development, and really start understanding how the disease happened—and how to design interventions.”

Related Links:
Scripps Research

Visit expo >

Gold Member

Pharmacogenetics Panel

VeriDose Core Panel v2.0

Verification Panels for Assay Development & QC
Seroconversion Panels

New

Calprotectin Assay

Fecal Calprotectin ELISA

New

Epstein-Barr Virus Test

Mononucleosis Rapid Test